Skip to content Skip to sidebar Skip to footer

All Posts

HomeAll Posts
April 29, 2026

Eli Lilly Just Hired an Algorithm: Inside the $2.25 Billion AI Drug Whisperer Deal With Profluent -( $LLY $IBB $XBI )

Eli Lilly’s (LLY) latest AI move reads less like a side project and more like a statement: the drugmaker is quietly trying to turn biology into software—and it just hired Profluent as one of its lead engineers.

Lilly Bets Big On AI-Authored Biology

Eli Lilly has signed a gene-editing and protein-design collaboration with AI startup Profluent, a deal that could be worth up to $2.25 billion if all development and commercial milestones are met. Under the agreement, Lilly secures exclusive rights to any medicines that emerge from Profluent’s platform, while Profluent receives an undisclosed upfront payment, committed R&D funding, and the potential for tiered royalties on net sales.

The companies are aiming at one of genetic medicine’s more stubborn challenges: building next-generation DNA editors, including recombinases, that can precisely insert long stretches of DNA into chosen locations in the genome—essentially moving from snipping genes to rewriting paragraphs. Specific disease targets and program counts have not yet been disclosed, underscoring how early the work is and how much of the value here lies in platform potential rather than near‑term product launches.

Inside Profluent’s “Programmable Biology” Playbook

Profluent, based in Emeryville, California, describes itself as a frontier AI company building large-scale foundation models for protein design—treating proteins less like mysteries of nature and more like outputs of a very large, very opinionated autocomplete engine. The startup has assembled what it calls the largest protein data resource in the world, an atlas of over 115 billion unique proteins, and has demonstrated that large language models can generate novel, functional proteins de novo rather than merely tweak existing ones.

Backed by investors including Altimeter Capital, Bezos Expeditions, Spark Capital, Insight Partners, and Air Street Capital, Profluent has raised roughly $150 million to scale its AI platform across therapeutics, diagnostics, agriculture, and biomanufacturing. Its mission is to make biology “programmable,” shifting drug discovery from painstaking trial‑and‑error toward engineered solutions where AI proposes bespoke proteins designed to solve specific clinical problems. In Lilly’s case, that means AI‑designed recombinases and other genetic tools that could one day make inserting full, healthy genes into diseased tissues feel less like moonshot science and more like precise infrastructure work.

A Deal Structure Built For Optionality

The financial architecture of the Lilly–Profluent pact says as much as the press release. Profluent stands to receive up to $2.25 billion through a ladder of development and commercial milestones, plus royalties on any eventual product sales, but the upfront payment remains undisclosed—classic “biobucks” territory that lets Lilly keep near‑term risk modest while preserving meaningful upside if the science hits.

For Lilly, the exclusive rights to drugs generated from Profluent’s platform create a kind of call option on the next generation of gene editing, giving the company first claim on AI‑designed therapies that could complement its existing franchises in obesity, diabetes, and other complex diseases. For Profluent, the structure effectively funds platform expansion while using Lilly’s global development and commercialization engine as the distribution layer for its AI‑authored biology. In Wall Street terms, Lilly keeps the balance sheet light today while buying long‑dated exposure to what some investors are already calling the “holy grail” of genetic medicine.

Part Of A Broader AI Supercycle At Lilly

This is not Lilly’s first AI pas de deux, and it likely won’t be its last. The company recently expanded its collaboration with Insilico Medicine, an

, in a deal that includes an initial payment of about $115 million and milestones that could take the total value to roughly $2.75 billion, with Lilly gaining exclusive rights to certain AI‑discovered drug candidates.

On the infrastructure side, Lilly has also teamed up with NVIDIA to build what the partners have described as one of pharma’s most powerful AI supercomputers, supported by up to $1 billion in joint investment and anchored by a co‑innovation lab in the San Francisco Bay Area. The idea is not just to “use AI” but to own industrial‑scale AI capabilities—from model training on millions of experiments to a TuneLab‑style platform where external biotechs can plug into Lilly’s models via federated learning. Put differently, Lilly is trying to be the place where biology meets compute at scale, and Profluent’s deal sits squarely inside that ambition.

What It Signals For Investors And Drug Development

For investors watching Eli Lilly, the Profluent partnership adds another layer to a thesis that’s already centered on durable growth in metabolic disease and an aggressive build‑out in next‑generation modalities. The company is effectively layering AI-driven discovery and gene editing tools on top of its commercial engine, betting that faster design cycles and more precise genetic interventions will help sustain its pipeline well into the 2030s.

The milestone-heavy structure, the absence of disclosed disease targets, and the emphasis on platform capabilities should also serve as a reminder: this is foundational R&D, not a near‑term earnings lever. Still, in an industry where traditional drug development can take a decade and cost more than $1 billion per asset, the prospect of AI‑designed editors and proteins that compress timelines and open up previously “undruggable” biology is the kind of asymmetric upside Wall Street tends not to ignore for long. If Lilly and Profluent are right, the next blockbuster might not just be discovered in the lab—it may be co‑written by an algorithm that treats DNA like code and proteins like a new asset class.

The Sources

  1. Bloomberg – “Lilly, Profluent Ink Deal on AI Drugs Worth Up to $2.25 Billion”
    https://www.bloomberg.com/news/articles/2026-04-28/lilly-profluent-ink-deal-on-ai-drugs-worth-up-to-2-25-billionbloomberg
  2. Business Wire – “Profluent Announces Strategic Partnership with Lilly to Develop AI-Designed Recombinases for Genetic Medicines”
    https://www.businesswire.com/news/home/20260428698315/en/Profluent-Announces-Strategic-Partnership-with-Lilly-to-Develop-AI-Desibusinesswire
  3. Reuters – “Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion”
    https://www.reuters.com/business/healthcare-pharmaceuticals/profluent-lilly-partner-genetic-medicine-deal-worth-up-225-billionreuters
  4. BioSpace – “Lilly, AI biotech Profluent ink $2.25B pact in search of genetic medicine ‘holy grail’”
    https://www.biospace.com/deals/lilly-ai-biotech-profluent-ink-2-25b-pact-in-search-of-genetic-medicine-holy-grailbiospace
  5. Yahoo Finance / Healthcare – “Profluent, Lilly partner in genetic medicine deal worth up to $2.25 billion”
    https://finance.yahoo.com/sectors/healthcare/articles/profluent-lilly-partner-genetic-medicine-111848875.htmlfinance.yahoo
  6. LinkedIn News – “Eli Lilly commits up to $2.25B to AI drug development”
    https://www.linkedin.com/news/story/eli-lilly-commits-up-to-225b-to-ai-drug-development-8738506/linkedin
  7. STAT News – “Eli Lilly enlists AI startup for next-generation gene editors”
    https://www.statnews.com/2026/04/28/eli-lilly-crispr-gene-editing-deal-profluent-ai/statnews
  8. Fierce Biotech – “Lilly pens $2.2B gene editing pact with Bezos-backed Profluent”
    https://www.fiercebiotech.com/biotech/lilly-pens-22b-pact-bezos-backed-profluent-work-recombinase-based-gene-editingfiercebiotech
  9. Simply Wall St – “Eli Lilly Expands Into AI DNA Editing With Profluent Enzyme Deal”
    https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-lly/eli-lilly/news/eli-lilly-expands-into-ai-dna-editing-with-profluent-enzyme-dealsimplywall
  10. Pharmaphorum – “AI start-up Profluent nabs Lilly as first big pharma partner”
    https://pharmaphorum.com/news/ai-start-profluent-nabs-lilly-first-big-pharma-partnerpharmaphorum
  11. American Pharmaceutical Review – “Profluent and Lilly Sign Multi-Program AI Partnership to Develop Recombinase-Based Gene Editing Medicines”
    https://www.americanpharmaceuticalreview.com/1315-News/625398-Profluent-and-Lilly-Sign-Multi-Program-AI-Partnership-to-Develop-Recombinase-Based-Gene-Editing-Medicinesamericanpharmaceuticalreview
  12. Indianapolis Business Journal – “Lilly signs $2.25B deal with California-based AI firm to develop genetic medicine”
    https://www.ibj.com/articles/lilly-signs-2-25b-deal-with-california-based-ai-firm-to-develop-genetic-medicineibj
April 29, 2026

UAE’s Big OPEC Breakup: Why Abu Dhabi Picked Now To Go Solo -( $CVX $OILK $XLE $XOM )

After six decades in the world’s most exclusive oil cartel, the United Arab Emirates has decided it would rather travel business class alone than economy in a crowd, announcing it will leave OPEC on May 1 in a move that strikes at the heart of the group’s cohesion and Saudi Arabia’s leadership. The decision lands at a moment when global crude markets are already taut, reshaped by war in Iran, a partial shutdown of the Strait of Hormuz, and a sharp drop in inventories that has left consumers uncomfortably familiar with the price board at their neighborhood filling station.

Why The Timing Looks “Just Right”

UAE Energy Minister Suhail Al Mazrouei insists the exit is not a dramatic walkout but a carefully timed pivot, stressing that the market is currently under‑supplied, which means the move should not “hugely impact” prices in the near term. With estimates that 10 to 12 million barrels per day of energy supplies have been taken off the market due to disruption around the Strait of Hormuz, the UAE sees an opening to respond more nimbly to demand without the procedural choreography of an OPEC meeting. In other words, Abu Dhabi is arguing that if the theater’s already half‑empty, one more person leaving the row won’t cause a stampede.

The Production Ambition Behind The Polite Language

Strip away the diplomatic phrasing, and a central ambition emerges: the UAE is currently pumping around 3.5 million barrels per day and is targeting 5 million barrels by 2027, a ramp‑up that sits uneasily with the discipline expected inside a quota‑bound cartel. Al Mazrouei emphasized that the country has “significant resources locally and globally” and framed the departure as a quest for the “freedom” to make decisions at the pace demanded by volatile conditions, while pledging not to “shock the market.” For investors, that sounds like a producer that wants to move from being a rule‑taker to a price‑sensitive, data‑driven swing player in its own right—think OPEC member no longer content with the ensemble role, auditioning for a solo.

Politics, Denials, And The Saudi Question

On the geopolitical front, the minister was quick to insist there is “no political linkage” to the decision and that ties with fellow producers, including Saudi Arabia, remain those of neighbors and partners, even as analysts have flagged a growing rift over regional issues ranging from Iran to Sudan and Yemen. The exit nonetheless lands as a symbolic setback for Riyadh, which has long relied on the UAE as one of its most impactful allies inside the group, particularly at a time when previous departures—such as Qatar in 2019 and Angola in 2024—have already chipped away at OPEC’s aura of unity. For all the assurances, markets will hear the polite “it’s not you, it’s me” and still wonder whether this is the start of a more competitive era among Gulf producers rather than a one‑off change of seating.

What Happens When The Strait Reopens

For now, the near‑term impact on supply and prices may remain muted because the Strait of Hormuz is still effectively shut and the lost barrels are doing the heavy lifting in keeping the market tight. The real test comes when flows normalize: if the UAE accelerates output without the constraints of a quota, and others follow suit to defend market share, investors could be looking at a slow‑motion tug‑of‑war between producer discipline and the temptation to monetize capacity in a high‑price world. That raises deeper questions about OPEC’s future relevance; a club that loses influential members and faces a growing cast of assertive non‑OPEC producers risks becoming less of a conductor and more of a very experienced, but no longer exclusive, house band.

The Investor’s Takeaway

For portfolio managers and energy investors, the UAE’s calculated uncoupling is less a dramatic plot twist than a structural development that could reshape how supply shocks, geopolitics, and capacity growth interact over the next several years. A producer targeting 5 million barrels per day by 2027 while promising to be a “responsible” actor suggests more liquidity and potentially more volatility at inflection points—particularly around any future reopening of the Strait of Hormuz and any policy response from Saudi Arabia and the remaining OPEC core. In classic Wall Street fashion, the message is that the cartel era is not over, but the cast is evolving—and investors who still trade oil like it’s 2010 may find that, in 2026, the script has quietly moved on.

Watch Related Video Now

The Sources

  1. CNBC – “United Arab Emirates to leave OPEC May 1, energy chief says still committed to oil price stability”
    https://www.cnbc.com/2026/04/28/uae-opec-oil-iran.htmlcnbc
  2. NPR – “The United Arab Emirates is quitting OPEC oil cartel after nearly 60 years”
    https://www.npr.org/2026/04/28/nx-s1-5802735/uae-leaves-opec-oilnpr
  3. Reuters – “UAE leaves OPEC in blow to global oil producers’ group”
    https://www.reuters.com/markets/commodities/uae-says-it-quits-opec-opec-statement-2026-04-28/reuters
  4. BBC – “Watch: Why has the UAE left Opec – and why does this matter?”
    https://www.bbc.com/news/videos/cz92wdvwek8obbc
  5. Al Jazeera – “UAE leaves OPEC in blow to oil cartel during war on Iran”
    https://www.aljazeera.com/news/2026/4/28/uae-leaves-opec-and-opecaljazeera
  6. CNBC – “UAE OPEC exit is not without precedence. Who could be next?”
    https://www.cnbc.com/2026/04/29/uae-opec-exit-oil-iran-war.htmlcnbc
  7. Yahoo Finance – “United Arab Emirates to leave OPEC+ in May, dealing blow to oil bloc”
    https://finance.yahoo.com/markets/article/united-arab-emirates-to-leave-opec-in-may-dealing-blow-to-oil-bloc-130449643.htmlfinance.yahoo
  8. Atlantic Council – “Why is the UAE leaving OPEC?”
    https://www.atlanticcouncil.org/content-series/fastthinking/why-is-the-uae-leaving-opec/atlanticcouncil
  9. YouTube – “UAE Announces Departure from OPEC, OPEC+ | OIL TO …”
    https://www.youtube.com/watch?v=rHSkGu9yfVsyoutube
  10. YouTube – “UAE To Quit Oil Exporting Groups OPEC, OPEC+ Amid Iran War”
    https://www.youtube.com/watch?v=tqOfcVdyG7Qyoutube
  11. YouTube – “UAE exit: Why a Gulf oil shift could hit fuel prices everywhere”
    https://www.youtube.com/watch?v=YWc8vMTkgK0youtube
  12. YouTube – “UAE Quits OPEC as War Upends Oil Markets and Gulf Tensions Rise”
    https://www.youtube.com/watch?v=msBAOAX6Qeoyoutube
April 28, 2026

April 28, 2026 – Nasdaq Nerves, Oil Jitters: Markets Ask If the Fed Got the Memo Yet -( $CVX $INTG $MCD $NOK $OPEN $SOAR Rise!)

U.S. stocks saw a split tape early on Tuesday, April 28, 2026, with the tech‑heavy Nasdaq sliding while the Dow rising, but investors sold off at the end as they balanced earnings, rising oil, and higher Treasury yields in front of Wednesday’s Fed decision. At the macro level, a fresh grind higher in yields tied to stalled U.S.–Iran peace talks and a dense data calendar kept risk appetite in check even as major indexes hovered near recent highs.

Equity markets

  • The S&P 500 finished .49 lower at after Monday’s record close, giving back part of its recent run but remaining near all‑time highs at 7,138.80.
  • The Nasdaq Composite underperformed, falling more sharply (.90%) as doubts around OpenAI‑linked and broader growth/AI names weighed on the mega‑cap complex.
  • The Dow Jones Industrial Average closed at 49,141.93, -.05%.
  • Sector leadership skewed toward energy and financials, supported by firmer oil prices just shy of $100/bbl and a steeper rate backdrop, while communication services, consumer‑facing growth, and parts of tech lagged.

As an illustration, think of today as a mild factor‑rotation day: growth/AI took a breather while cyclicals, value, and balance‑sheet beneficiaries of higher rates quietly picked up the baton.

Rates, geopolitics, and oil

  • U.S. Treasury yields rose across the curve, with the 10‑year yield climbing a bit over 2 basis points to around 4.36% and the 2‑year edging higher to roughly 3.82%, reflecting both geopolitical risk and pre‑Fed positioning.
  • The 30‑year yield also ticked up, approaching 4.96%, extending the bear‑flattening theme seen across global sovereign markets.
  • The move was catalyzed in part by news that U.S.–Iran peace negotiations have hit an impasse, shrinking the perceived odds of a near‑term deal and prolonging uncertainty around the conflict and shipping lanes.
  • Oil prices drifted higher as traders weighed stalled talks, the UAE’s plan to exit OPEC as of May 1, and signs that China may restart some crude exports after earlier war‑related restrictions.

This combination of higher yields and firmer crude reinforced a defensive bias on the margins, particularly in long‑duration growth and rate‑sensitive pockets of the market.

Key macro data and central banks

  • Tuesday sat in the middle of a macro‑heavy week, with investors watching U.S. releases such as ADP employment, the S&P/Case‑Shiller home price index, and Conference Board consumer confidence for confirmation that domestic demand remains resilient into mid‑year.
  • These prints feed directly into the market’s narrative on the “soft‑landing or not” debate, as labor data, housing prices, and sentiment all shape expectations for future consumer spending, credit demand, and bank asset quality.
  • Globally, markets also tracked the Bank of Japan’s policy decision and press conference for any shift in its normalization path, given the implications for the yen, carry trades, and broader risk appetite.
  • The macro backdrop remains framed by April’s IMF World Economic Outlook, which projects global growth easing to roughly the low‑3% area for 2026, with inflation re‑accelerating modestly before resuming its downtrend in 2027 as Middle East war dynamics feed through energy and trade channels.

Against that backdrop, traders largely treated today’s data as incremental rather than narrative‑changing, keeping the focus on Wednesday’s Fed meeting and updated guidance from outgoing Chair Jerome Powell.

Earnings, sectors, and technicals

  • Earnings season continued to drive idiosyncratic moves, with a mix of beats and cautious outlooks reinforcing a “show‑me” tone, especially for richly valued growth and AI‑themed names.
  • Energy stocks benefited from higher crude and renewed geopolitical risk premia, while financials drew support from the steeper curve and the prospect of better net interest margins if rates stay higher for longer. i.e. Chevron (CVX) closed at $188.36, +1.94%.
  • On a technical basis, the S&P 500 remains overbought by several momentum measures after notching fresh closing highs on Monday; short‑term indicators suggest the rally is “stretching” and vulnerable to a few down days even as the medium‑term trend stays intact,
  • Momentum is still positive, but MACD has begun to lose some strength, which historically precedes consolidation phases rather than immediate trend reversals when breadth remains constructive.

From a trading perspective, this looks like a late‑cycle extension of the advance where marginal sellers are emerging into strength, but without clear evidence yet of a decisive top in the major indexes.

Big picture for investors

  • The prevailing setup is one where geopolitics and higher yields are starting to nibble at risk appetite, but they have not yet overwhelmed solid earnings and still‑healthy growth expectations.
  • For asset allocators, that argues for modestly upgrading quality and balance‑sheet strength, keeping some exposure to energy and financials as hedges against rate and oil volatility, and being selective in high‑multiple growth after a powerful run..
  • Near term, tomorrow’s Fed decision and press conference are likely to be the next major catalyst for both equities and Treasuries, with any hint of a more patient or more hawkish stance quickly repricing rate‑cut expectations into the back half of 2026.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Eupraxia Pharmaceuticals (EPRX, $7.11)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, announced (April 21) 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks. This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated”.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Modular Medical (MODD, $4.31)

  • Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
  • Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $42.50, +9.11%)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group, Inc. (SOAR, +14.16%) & M2i Global, Inc. (MTWO)

  • M2i Global, Inc., a company specializing in the development and execution of a complete global value supply chain for critical minerals, announced (April 28), in connection with the the Agreement and Plan of Merger and Reorganization, dated as of July 28, 2025, by and among M2i Volato Group, Inc. (“Volato”) (NYSE American: SOAR), and Volato Merger Subsidiary, Inc., , that the sole holder of M2i’s Series A Super Voting Preferred Stock, entitled to 10,000 votes per share of voting stock, voted by written consent in favor of the Company’s merger with Volato whereby M2i will become a wholly-owned subsidiary of Volato. At the closing of the merger, the name of Volato will change to M2i Global.
  • Volato Group, Inc. (April 16) announced that it will hold a special meeting of shareholders on May 7, 2026 to vote on the previously announced proposed merger with M2i Global, Inc. (“M2i Global”). Shareholders of record as of the close of business on April 17, 2026 will be entitled to vote at the special meeting. The Company expects the merger to close shortly after the meeting, subject to shareholder approval and the satisfaction of customary closing conditions. Under the terms of the merger agreement, M2i Global will merge with a wholly owned subsidiary of Volato, with M2i Global continuing as the surviving entity and a wholly owned subsidiary of Volato. Upon completion of the transaction, existing M2i Global shareholders are expected to own approximately 85% of the combined company, while Volato shareholders are expected to own approximately 15%, on a fully diluted basis (excluding warrants). The combined company is expected to leverage M2i Global’s capabilities across mining, refining, and recycling of critical minerals alongside Volato’s expertise in software, data systems, and operational execution, creating a scalable, technology-enabled platform focused on strengthening domestic supply chains.
  • Volato Group, Inc. (NYSE American: SOAR) (the “Company” or “Volato”) and M2i Global, Inc. (OTCQB: MTWO) (“M2i Global”) (April 13) announced that the U.S. Securities and Exchange Commission has declared effective the Registration Statement on Form S-4 (File No. 333-292132) relating to Volato’s proposed merger with M2i Global, formally advancing the transaction into its shareholder approval and closing phases. Volato is proceeding with distribution of the definitive proxy statement/prospectus and a special meeting of shareholders is expected to be held on May 7, 2026. Shareholders of record as of April 17, 2026 will be entitled to vote on the proposed transaction.
  • flyExclusive (NYSE American: FLYX), the vertically integrated private aviation company, announced (March 25) two milestones in its proprietary technology development: the filing of a utility patent application for a novel aircraft schedule optimization architecture, and the availability of Contrails, its Flight Management System, to other Part 135 operators beginning in Q2 2026. Both announcements coincide with the company’s presence at the NBAA Schedulers & Dispatchers Conference 2026 in Cleveland. “We have spent years building flyExclusive into one of the most operationally capable private aviation companies in the country. Contrails is how we make that expertise available to the broader industry—and the intellectual property behind it reflects the depth of investment we have made in solving problems that matter to every serious operator. We believe the right technology, built by people who actually run flights, changes what is possible in this industry. Today we are unable to source lift for nearly 300 trip requests per day. We believe Contrails will allow us to address that demand far more efficiently—both within our own operation and through coordination with other operators—and that represents a material revenue opportunity for flyExclusive and for all participating operators.”
  • Volato Group, Inc. announced (March 10) that it has entered into an amendment to its Aircraft Management Services Agreement with flyExclusive, Inc. (“FLYX”) providing for the sale of certain legacy intellectual property assets. The agreement provides for consideration valued at approximately $1.3 million, payable in FLYX Class A common stock, subject to customary conditions. The assets relate to legacy intellectual property developed during earlier stages of the Company’s technology initiatives and are not part of Volato’s current operating platforms. Volato continues to evaluate opportunities to streamline its asset base and focus resources on strategic priorities, including the continued development of its core software platforms and the pending business combination with M2i Global, Inc.
  • On Feb. 4, M2i Global,Inc.along with Volato Group, Inc. announced that Titanium X has initiated its first shipment of titanium ore from Western Australia to the U.S. under its collaboration agreement.

NVIDIA (NVDA, $213.17) & Nokia (NOK, $11.30, +5.48%)

  • Nokia just served Wall Street a quietly confident Q1, the kind of quarter that doesn’t light up the meme feeds but does make long-only portfolio managers reach for their notebooks instead of the antacids.
  • In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
  • NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $292.39, +.75%)

  • Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock . The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Opendoor (OPEN, $5.48, +1.67%)

  • April 16, Opendoor Technologies Inc. (OPEN) announced that it will report first quarter 2026 financial results for the period ended March 31, 2026 following the close of the market on Thursday, May 7, 2026. On May 7, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company’s business and financial results. We invite shareholders to participate directly through Robinhood’s Say Technologies platform by visiting https://app.saytechnologies.com/opendoor-2026-q1
  • Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
  • Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

Tesla (TSLA, $376.02)

Reportedly, Tesla recently and unexpectedly swung to positive free cash flow in the first quarter, a neat trick for a company many on Wall Street still expected to be busily torching cash. The electric-vehicle maker has yet to fully open the spending spigots on artificial intelligence and added manufacturing capacity, suggesting the real splurge is still to come.

Reportedly, Ross Gerber of Gerber Kawasaki believes that combining Tesla and SpaceX could create a Berkshire Hathaway–style powerhouse focused on artificial intelligence.

Serina Therapeutics (NYSE: SER, $1.85, +2.78%)

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.

What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.

Walmart (WMT, $127.59)

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. 

The Sources

  1. Yahoo Finance – “Stock market today: Tuesday, April 28 – Dow, Nasdaq, S&P, oil rises, earnings in focus”
    https://finance.yahoo.com/markets/stocks/live/stock-market-today-tuesday-april-28-dow-nasdaq-sp-oil-rises-earnings-in-focus-225503557.htmlwsj
  2. CNBC – “Treasury yields rise as U.S.-Iran peace talks hit an impasse”
    https://www.cnbc.com/2026/04/28/treasury-yields-us-iran-peace-talks-at-impasse.htmlcnbc
  3. Wall Street Journal – “Stock Market Today” live coverage (April 28, 2026)
    https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-04-28-2026/card/rJnaJmBT0fH7Xgg4CdVbwsj
  4. Axon Markets – “Daily Market Update: 28 April, 2026”
    https://www.axonmarkets.com/blog/daily-market-update-28-april-2026axonmarkets
  5. FullyInformed – “Stock Market Outlook For Tue Apr 28 2026 – Still Overbought But …”
    https://www.fullyinformed.com/stock-market-outlook-for-tue-apr-28-2026-still-overbought-but-new-highs/fullyinformed
  6. CNBC – “Stock market news for April 27, 2026” (context for prior session)
    https://www.cnbc.com/2026/04/26/stock-market-today-live-updates.htmlcnbc
  7. IMF – “World Economic Outlook, April 2026”
    https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026imf
  8. Investing.com – “Global Economic Outlook: Analyzing the IMF’s April 2026 Report”
    https://www.investing.com/analysis/global-economic-outlook-analyzing-the-imfs-april-2026-report-200678466investing
  9. Sergey Tereshkin – “Economic Events on April 28, 2026: Bank of Japan, EU Inflation …”
    https://sergeytereshkin.com/publications/economic-events-april-28-2026sergeytereshkin
  10. Crypto Briefing – “US-Iran nuclear deal talks stall, Treasury yields climb”
    https://cryptobriefing.com/us-iran-nuclear-deal-talks-stall-treasury-yields-climb/cryptobriefing
  11. GoldSeek – “Treasury yields rise as U.S.-Iran peace talks hit an impasse”
    https://goldseek.com/article/treasury-yields-rise-us-iran-peace-talks-hit-impassegoldseek
  12. NYSE – Market data and index levels (reference for sector and index performance)
    https://www.nyse.com/indexnyse
April 28, 2026

Healthcare’s Quiet Rally: Incyte, Pfizer & Eupraxia Put Some Spring in Wall Street’s Step – ( $EPRX $INCY $PFE $XBI )

Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why ‘boring’ can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a picture of steady earnings power, disciplined deal-making and under‑the‑radar innovation in difficult diseases. Incyte is outpacing first‑quarter expectations, Pfizer is stitching together deals and partnerships to keep its growth story beating strongly, and Eupraxia is stepping onto a global stage at Digestive Disease Week with fresh data in eosinophilic esophagitis. For investors who prefer cash flows and steady progress rather than to casino vibes, it is the kind of trio that can possibly make a defensive sector look surprisingly offensive.

Incyte: Earnings Beat With Room To Run

Incyte entered earnings season with the Street looking for around 1.23 billion dollars in first‑quarter revenue and mid‑teens percentage growth. Instead, the company delivered roughly 1.27 billion dollars, representing about 20 percent year‑on‑year growth and a solid beat versus consensus estimates. That is the sort of performance that gets analysts to sharpen their price targets and portfolio managers to revisit an under‑owned name.

Behind the headline numbers, the drivers are familiar but reassuring: durable demand for myelofibrosis drug Jakafi and ongoing traction for Opzelura in atopic dermatitis and vitiligo, complemented by a growing royalty stream from Novartis’ ex‑U.S. Jakavi franchise. Incyte has also been layering in newer oncology and immunology launches such as Zynyz and Pemazyre, creating a broader base that reduces dependence on any single product. For a mid‑cap biopharma, that diversification is the biotech equivalent of swapping a unicycle for a four‑door sedan.

Investors heading into the print already knew Incyte has a habit of meeting or exceeding revenue expectations, but this quarter’s beat reinforces that history rather than merely extending it. Analysts were modeling a deceleration in growth from the high‑teens pace of the prior year, yet the company still managed to post a figure that clears the bar set just days earlier. In a market where guidance “adjustments” have become a seasonal sport, delivering upside without fanfare is its own quiet flex.

Pfizer: Deal‑Making To Keep The Heart Of The Story Beating

While Incyte is impressing with execution, Pfizer is working from a larger playbook: using its balance sheet, pipeline and partnerships to reset the post‑pandemic narrative. The company has been steadily adding external innovation and commercial levers, including a partnership valued at up to 530 million dollars with Novavax in vaccines and a series of moves in oncology and metabolic disease. At the same time, it has kept its shareholder‑friendly reputation intact, recently declaring a 43‑cent second‑quarter 2026 dividend—marking the 350th consecutive quarterly payout.

The Novavax deal seems to underscores Pfizer’s willingness to pay for optionality in vaccine technology rather than rely solely on internal R&D, a strategy that gives the company multiple shots on goal as global immunization needs evolve. Management has struck a similar tone in obesity, where the acquisition of Metsera provides a second attempt at a category that could reach 150 billion dollars by 2030, with a mix of monthly injectables and oral combination therapies aimed at long‑term tolerability. It is a reminder that when Pfizer walks away from one program, it often reappears at the next table with a larger stack of chips.

For income‑oriented investors, the uninterrupted dividend stream speaks as loudly as the deal headlines. In an environment where rate expectations oscillate daily and bond yields can whipsaw on every data release, a large‑cap pharma name quietly sending out its 350th consecutive quarterly check has a certain old‑world charm. Add in the potential upside from oncology assets like Padcev, which recently secured FDA priority review for use in muscle‑invasive bladder cancer, and the case for keeping Pfizer in the core of a health‑care allocation grows harder to ignore.

Eupraxia: A Small Cap Steps Onto The Big Digestive Stage

If Pfizer is the blue‑chip stalwart and Incyte the seasoned mid‑cap compounder, Eupraxia Pharmaceuticals is the smaller, high‑beta story trying to solve a very particular kind of pain—literally and figuratively. The company is heading to Digestive Disease Week, one of the premier GI conferences, to present four abstracts featuring its lead asset EP‑104GI in eosinophilic esophagitis. The presentations will cover 36‑week data from the Phase 1b/2 RESOLVE trial, including histology, endoscopy and symptom durability measures.

Eosinophilic esophagitis remains a difficult‑to‑treat chronic inflammatory condition, and patients often cycle through dietary changes, proton pump inhibitors and other therapies with incomplete relief. Eupraxia is using its Diffusphere technology to deliver a long‑acting corticosteroid formulation, aiming to maintain local benefit in the esophagus while limiting systemic exposure. The 36‑week durability data on tissue inflammation, fibrosis and dysphagia symptoms are designed to show that this approach can sustain clinical benefit well beyond the honeymoon period of many experimental therapies.

The company plans to complement the scientific spotlight with a key opinion leader‑led investor event focused on recurrent esophageal strictures and the broader commercial opportunity in eosinophilic esophagitis. That dual‑track strategy—win over gastroenterologists in the morning, investors in the afternoon—has become a hallmark of ambitious small‑cap biotechs looking to punch above their weight. For shareholders willing to tolerate early‑stage risk, the upcoming DDW data could act as a meaningful catalyst in a space that has seen relatively few differentiated entrants.

What It Means For Investors

Taken together, the latest developments across these three companies sketch a health‑care landscape that is more dynamic than the sector’s defensive reputation suggests. Incyte’s revenue beat and continued product diversification reinforce the idea that mid‑cap biopharma can deliver both growth and resilience when execution lines up with a maturing portfolio. Pfizer’s steady dividend, high‑profile transactions and pipeline repositioning show how a pharma giant can use scale not just to defend incumbency, but to re‑enter fast‑growing categories with renewed ambition.

At the other end of the market‑cap spectrum, Eupraxia (NASDAQ: EPRX) highlights the innovation happening in niche, high‑unmet‑need diseases that rarely make the front page but can create meaningful shareholder value if clinical data cooperate. For portfolio construction, the trio offers a neat illustration of how health‑care exposure can be layered: a dividend‑paying large cap, a growth‑oriented mid cap and a catalyst‑driven small cap, each tapping a different part of the risk‑reward spectrum.

In a market captivated by the latest AI narrative, these updates are a reminder that there is still alpha to be found in more traditional drug development—so long as investors are willing to read beyond the ticker tape and occasionally, perhaps, the digestive conference agenda.

The Sources

  1. Incyte earnings and outlook – “Incyte (NASDAQ:INCY) Exceeds Q1 CY2026 Expectations” (Yahoo Finance)
    https://finance.yahoo.com/markets/stocks/articles/incyte-nasdaq-incy-exceeds-q1-111842338.htmlfinance.yahoo
  2. Incyte earnings snapshot – “Incyte: Q1 Earnings Snapshot” (Yahoo Finance)
    https://finance.yahoo.com/sectors/healthcare/articles/incyte-q1-earnings-snapshot-111158470.htmlfinance.yahoo
  3. Incyte earnings preview – “Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?” (Yahoo Finance)
    https://finance.yahoo.com/sectors/healthcare/articles/incyte-gears-report-q1-earnings-124900805.htmlfinance.yahoo
  4. Incyte earnings overview – “Incyte Earnings: What To Look For From INCY” (Yahoo Finance)
    https://finance.yahoo.com/markets/stocks/articles/incyte-earnings-look-incy-114855695.htmlfinance.yahoo
  5. Incyte results timing – “Incyte to Report First Quarter Financial Results” (Yahoo Finance)
    https://finance.yahoo.com/markets/stocks/articles/incyte-report-first-quarter-financial-120000375.htmlfinance.yahoo
  6. Pfizer obesity strategy – “JPM26: Pfizer’s Metsera deal supercharges its obesity strategy” (Yahoo Finance)
    https://finance.yahoo.com/news/jpm26-pfizer-metsera-deal-supercharges-195036915.htmlfinance.yahoo
  7. Eupraxia SEC filing and DDW data – “Eupraxia to Present EP-104GI Data at DDW 2026 | EPRX SEC Filing” (StockTitan)
    https://www.stocktitan.net/sec-filings/EPRX/6-k-eupraxia-pharmaceuticals-inc-current-report-foreign-issuer-c59848386b1a.htmlstocktitan
  8. Incyte Q1 2026 earnings summary – “Incyte Q1 2026 Earnings Report” (MarketBeat)
    https://www.marketbeat.com/earnings/reports/2026-4-28-incyte-co-stock/marketbeat
  9. Pfizer oncology update – “Pfizer and Astellas secure FDA priority review for Padcev MIBC …” (Yahoo Finance)
    https://www.yahoo.com/news/articles/pfizer-astellas-secure-fda-priority-103556636.htmlyahoo
  10. Eupraxia DDW announcement – “Eupraxia Pharmaceuticals to Present at Digestive Disease Week …” (Yahoo Finance)
    https://finance.yahoo.com/sectors/healthcare/articles/eupraxia-pharmaceuticals-present-digestive-disease-110000292.htmlfinance.yahoo
  11. Incyte analytics background – “Incyte Corporation (INCY) – Analysis” (Yahoo Finance)
    https://finance.yahoo.com/quote/INCY/analysis/finance.yahoo
  12. Pfizer dividend announcement – “Pfizer Declares Second-Quarter 2026 Dividend” (Yahoo Finance)
    https://finance.yahoo.com/markets/stocks/articles/pfizer-declares-second-quarter-2026-204500370.htmlfinance.yahoo
  13. Eupraxia EP‑104GI overview – “Eupraxia Pharmaceuticals to Showcase EP‑104GI Data at Digestive …” (The Globe and Mail)
    https://www.theglobeandmail.com/investing/markets/stocks/EPRX-Q/pressreleases/1472563/eupraxia-pharmaceuticals-to-showcase-ep-10/theglobeandmail
  14. Incyte expectations article – “Incyte (INCY) Reports Next Week: Wall Street Expects Earnings …” (Yahoo Finance)
    https://finance.yahoo.com/markets/stocks/articles/incyte-incy-reports-next-week-140020145.htmlfinance.yahoo
  15. Pfizer cost‑savings / drug pricing context – “Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug …” (Yahoo Finance)
    https://finance.yahoo.com/news/pfizer-launches-cost-savings-program-000900467.htmlfinance.yahoo
April 27, 2026

April 27, 2026 – Nasdaq Strikes Record Highs & Oil Jumps While FOMC Hangs In The Wings -( $EPRX $INTG $NOK $NVDA $ORKA $TSLA Rise!)

U.S. stocks traded mixed as the AI/tech powered Nasdaq established a new record high on Monday, April 27, 2026. Investors weighed record‑level indices against a fresh jump in oil prices ($96.68/bbl) and rising geopolitical risk around the Strait of Hormuz.

U.S. equity market snapshot

Major indices hovered near recent highs but showed a cautious tone as the session unfolded.

  • The S&P 500 was roughly flat, rising .12% as large caps consolidated after last week’s record close.
  • The Dow Jones Industrial Average edged .13% lower.
  • The Nasdaq Composite rose about 0.20% establishing a new record high
  • Small caps edged slightly higher with the Russell 2000 up around 0.04%, reflecting some rotation into domestically focused cyclicals.

Below the surface, the tone was one of consolidation rather than capitulation, with investors reluctant to add broad risk ahead of key macro data later in the week.

Macro and policy backdrop

Macro attention centered on a combination of geopolitics, oil, and the evolving growth‑inflation mix highlighted in recent outlooks.

  • Oil prices pushed higher after reports that Iran, via Pakistani mediators, floated a proposal to reopen the Strait of Hormuz and end the regional conflict, while deferring nuclear talks.
  • The same reports noted that after President Donald Trump canceled peace talks in Islamabad over the weekend, hopes returned for peace somewhat on Monday.
  • The IMF’s April 2026 World Economic Outlook projects global growth slowing to about 3.1% in 2026, with headline inflation expected to tick up modestly before easing in 2027, reinforcing the “slower growth, stickier inflation” narrative.

For traders, that combination keeps the focus on upcoming FOMC communication and high‑frequency data on growth, prices, and consumption, with several desks flagging this week’s Fed decision and the continuation of mega‑cap earnings as pivotal catalysts.

Sector and thematic moves

Sector performance reflected the day’s blend of higher oil, record‑level valuations, and geopolitical uncertainty.

  • Energy led on the back of rising crude, as investors priced in continued supply risk even as diplomatic efforts around the Strait of Hormuz emerged.
  • Cyclicals and small‑cap value gained modestly, consistent with the Russell 2000’s outperformance as investors sought catch‑up opportunities away from stretched mega‑caps.
  • Technology traded higher; the Nasdaq’s slight rise showed a high‑multiple growth and AI beneficiaries.
  • Defensive groups like utilities and staples were mostly stable, with investors balancing higher input costs from energy against still‑solid consumer demand.

This pattern is broadly consistent with the IMF’s message that higher energy prices and geopolitical risk are likely to weigh more heavily on emerging markets and energy‑importing regions, while leaving U.S. growth slower but still positive.

Global and cross‑asset context

Overnight and cross‑asset action framed Monday’s U.S. session as part of a broader, cautious risk‑on stance.

  • In Asia, most major markets closed higher, with Japan’s Nikkei 225 and Korea’s Kospi both notching solid gains as investors reacted to the same Strait of Hormuz headlines and remained focused on AI and tech leadership.
  • European equities were modestly higher, led by energy and retail, as higher oil prices buoyed producers while resilient consumption supported discretionary names.
  • On the macro side, IMF commentary and regional finance‑ministry forecasts continued to highlight a 2026 environment of domestically driven growth, higher energy costs, and trade headwinds, especially in Europe and parts of the Middle East and Central Asia.

In fixed income and FX, the combination of firmer oil and geopolitics supported a mild bid in safe‑haven assets and underpinned the dollar, but moves remained contained as markets await clearer signals from the Fed and this week’s data slate.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Oruka Therapeutics, Inc. (ORKA, $76.39, +10.66%)

Oruka Therapeutics, a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases, today announced positive interim results from its EVERLAST-A Phase 2a trial of ORKA-001, a novel half-life extended IL-23p19 monoclonal antibody, in moderate-to-severe plaque psoriasis. After the closed today, Oruku also announced that it has commenced an underwritten public offering of $500 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Oruka expects to grant the underwriters a 30-day option to purchase up to an additional $75 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed public offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. All of the shares of common stock and pre-funded warrants are being offered by Oruka.

Broadcom (AVGO, $418)

Broadcom’s latest AI alliance with Google parent Alphabet Inc. (GOOGL, GOOG) and Anthropic is less a routine chip deal and more a declaration that the quiet power behind the cloud plans to stay loud for the next decade. The three-way pact locks in custom AI silicon and multi‑gigawatt compute capacity that could reshape who really controls the tollbooths on the generative AI superhighway.

Eupraxia Pharmaceuticals (EPRX, $7.21, +.70%)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks. This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated”.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Eupraxia announced (March 17) positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). “We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose of the Phase 1b/2a portion of the RESOLVE study,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We believe this type of response based on a single administration procedure would represent a compellingly different option for EoE patients. Importantly, the response that we are observing across cohorts 4-9 has increased as patients progress through the study through to week 24. We believe this demonstrates the importance of stable, continuous long-term local steroids in tamping down signs of inflammation quickly and acting on fibrosis in the longer term. Also, as previously reported, we continue to be encouraged by the safety profile that we have observed with EP-104GI. Currently, with 31 patients dosed in the Phase 1b/2a study, and over 220 months of follow up, there have been no reported serious adverse events.”

Modular Medical (MODD, $4.35)

  • Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
  • Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $39.40, +7.71%)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group, Inc. (SOAR) & M2i Global, Inc. (MTWO)

NVIDIA (NVDA, $216.61, +4.01%) & Nokia (NOK, $10.76, +2.87%)

  • Nokia just served Wall Street a quietly confident Q1, the kind of quarter that doesn’t light up the meme feeds but does make long-only portfolio managers reach for their notebooks instead of the antacids.
  • In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
  • NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $290.21)

  • Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock . The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Opendoor (OPEN, $5.39)

  • April 16, Opendoor Technologies Inc. (OPEN) announced that it will report first quarter 2026 financial results for the period ended March 31, 2026 following the close of the market on Thursday, May 7, 2026. On May 7, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company’s business and financial results. We invite shareholders to participate directly through Robinhood’s Say Technologies platform by visiting https://app.saytechnologies.com/opendoor-2026-q1
  • Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
  • Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

Tesla (TSLA, $387.67, +.63%)

Reportedly, Tesla unexpectedly swung to positive free cash flow in the first quarter, a neat trick for a company many on Wall Street still expected to be busily torching cash. The electric-vehicle maker has yet to fully open the spending spigots on artificial intelligence and added manufacturing capacity, suggesting the real splurge is still to come.

Serina Therapeutics (NYSE: SER, $1.80)

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.

What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.

Walmart (WMT, $127.59)

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. 

The Sources

  1. Yahoo Finance – “Stock market today: S&P 500, Nasdaq notch fresh records, oil edges higher”
    https://finance.yahoo.com/markets/stocks/live/stock-market-today-monday-april-27-232226050.htmlfinance.yahoo
  2. TheStreet – “Stock Market Today (Apr. 27, 2026): Dow futures edge lower, oil climbs on Iran Strait proposal report”
    https://www.thestreet.com/latest-news/stock-market-today-apr-27-2026-updatesthestreet
  3. CNBC – “S&P 500 drifts higher to record levels, but gains capped as oil rises” (April 26, 2026)
    https://www.cnbc.com/2026/04/26/stock-market-today-live-updates.htmlcnbc
  4. Yahoo Finance – Homepage / live markets context (indices, sector moves)
    https://finance.yahoo.comfinance.yahoo
  5. Yahoo Finance – “Daily Market Coverage Apr. 27, 2026 9AM–11AM (ET)” (video)
    https://www.youtube.com/watch?v=lT8b-ZWj7bwyoutube
  6. Yahoo Finance – “Daily Market Coverage Apr. 27, 2026 3PM–5PM (ET)” (video)
    https://www.youtube.com/watch?v=eUBJYzQywHgyoutube
  7. IMF – “World Economic Outlook, April 2026”
    https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026imf
  8. Investing.com – “Global Economic Outlook: Analyzing the IMF’s April 2026 Report”
    https://www.investing.com/analysis/global-economic-outlook-analyzing-the-imfs-april-2026-report-200678466investing
  9. Czech Ministry of Finance – “Macroeconomic Forecast – April 2026”
    https://mf.gov.cz/en/fiscal-policy/macroeconomic-analysis/macroeconomic-forecast/2026/macroeconomic-forecast-april-2026-63635mf
  10. Fidelity – “Weekly market update | Market recap” (for framing of market narrative and flows)
    https://www.fidelity.com/learning-center/trading-investing/weekly-market-updatefidelity
  11. J.P. Morgan Asset Management – “Weekly Market Recap” (PDF)
    https://am.jpmorgan.com/content/dam/jpm-am-aem/americas/us/en/insights/market-insights/wmr/weekly_market_recap.pdfjpmorgan
April 27, 2026

From Penalty Box to Power Player: Nokia’s AI Networks Put a New Ring in Its Step -( $BAC $NOK $NVDA $TMUS )

Nokia’s (NOK) latest quarter now comes with something Wall Street loves even more than improving margins: a fresh “Buy” sticker from a long-time holdout. Argus has joined the growing chorus of bullish analysts, effectively declaring that this is no longer your early‑2010s turnaround story, but a full‑fledged AI infrastructure play.

A Solid Quarter That Finally Got Noticed

Nokia opened 2026 with net sales of about EUR 4.5 billion, up roughly 4% year over year on a comparable basis (2% reported), not bad for a company that once seemed permanently stuck in telecom’s slow lane. Comparable gross margin expanded by 320 basis points to 45.5%, while comparable operating margin improved by about 200 basis points, signaling that the profit engine is no longer idling. Comparable operating profit jumped 54% to EUR 281 million, turning last year’s grinding reset into this year’s margin narrative.

Earnings per share landed at EUR 0.05 on a comparable basis and EUR 0.02 reported—no champagne moment, but a clear step away from the red ink of prior periods. Free cash flow of roughly EUR 0.6 billion pushed net cash to EUR 3.8 billion, giving Nokia the kind of balance sheet that lets management talk about strategy without creditors clearing their throats in the background. CEO Justin Hotard labeled it “a solid start to the year,” which, in the cautious dialect of network equipment, translates loosely to “we’re finally getting some credit for this.”

AI & Cloud: From Buzzword to Business Model

For most of the market, “AI strategy” lives on slides; for Nokia, it’s starting to show up in invoices. Net sales from AI and Cloud customers surged 49% year over year in Q1 and now account for about 8% of group sales, up from a rounding error to a genuine growth driver. The company also booked around EUR 1 billion in orders from these customers during the quarter, and Network Infrastructure posted a book‑to‑bill comfortably above one, suggesting that the AI wave is still building, not cresting.

The story behind the numbers is a deliberate pivot toward AI data centers and hyperscalers that need high‑capacity optical and IP networks more than they need yet another smartphone app. Optical Networks and IP Networks are being wired directly into the global AI build‑out, turning what used to be a cyclical hardware cycle into something that increasingly resembles a multi‑year infrastructure program. Nokia’s collaborations with cloud and carrier partners—ranging from AI‑enhanced RAN initiatives built on anyRAN and NVIDIA platforms to new enterprise‑grade Wi‑Fi 7 and fiber LAN solutions—are designed to keep it sitting in the middle of the AI traffic rather than watching it drive by.

Network Infrastructure: The Adult in the Room

The grown‑up part of Nokia’s portfolio continues to behave like one. Network Infrastructure net sales grew 6% year over year on a constant currency and portfolio‑adjusted basis, led by a 20% surge in Optical Networks revenue. IP Networks grew roughly 3%, with management signaling expectations for faster growth in the second quarter and across 2026 as AI and Cloud orders move from contract signatures to recognized revenue.

Fixed Networks, meanwhile, shrank 13%, not because demand evaporated, but because Nokia tilted the mix toward higher‑margin products rather than chasing every low‑margin line item in broadband. The core fiber OLT business remains broadly flat, but the company points to a growing pipeline in key markets, suggesting this is more of a pause for breath than a last gasp. For a sector long criticized for undisciplined pricing, Nokia’s willingness to trade some volume for margin looks almost radical—and is one of the reasons analysts now talk about “quality of growth” instead of just growth.

Nokia’s Core Segments at a Glance

SegmentQ1 2026 Trend / HighlightStrategic Angle
Network Infrastructure6% growth; Optical +20%, IP +3% (constant currency and portfolio) Core AI and Cloud backbone, raised 2026 growth targets 
AI & Cloud CustomersSales +49%; ~8% of group revenue; ~EUR 1B orders Emerging growth pillar tied to hyperscaler and data‑center demand 
Fixed NetworksSales −13% as mix shifts to higher margin Tactical reset to protect profitability
Mobile Infrastructure~3% growth; 8.9% operating margin Steady support act while AI/optical lead growth 

Mobile Infrastructure: Supporting Role, Not Box Office

Nokia’s Mobile Infrastructure segment is unlikely to trend on social media, but it remains essential to the earnings script. Net sales grew around 3% year over year on a constant currency basis, supported by Core Software and Technology Standards, with Radio Networks roughly flat amid ongoing competitive pressure and cautious operator spending. The segment posted an operating margin of 8.9% in Q1, helped by the absence of last year’s one‑off charges and by early benefits from the simplified business structure.

Management says the integration of the revamped Mobile Infrastructure setup is on track, with a focus on expanding gross margin over time rather than chasing every incremental base station deal. In a world where 5G headlines have cooled but AI‑RAN experiments are heating up, Nokia’s anyRAN software and AI‑assisted RAN initiatives with partners such as Orange, T‑Mobile (TMUS), and NVIDIA (NVDA) quietly position Mobile Infrastructure as a future beneficiary of smarter, not just faster, wireless networks.

Guidance: Raising Targets Where It Matters

The real inflection point is in the outlook. Nokia now expects Network Infrastructure net sales to grow between 12% and 14% in 2026, lifted from prior expectations as AI and Cloud demand accelerates and Optical/IP orders pile up. Within that, Optical and IP Networks together are projected to grow between 18% and 20%, effectively crowned as the structural growth engines of the company.

At the group level, Nokia reaffirmed its full‑year comparable operating profit guidance of EUR 2.0 billion to EUR 2.5 billion and noted that it is currently tracking somewhat above the midpoint of that range. The company also expects Q2 2026 net sales to rise 5% to 9% quarter over quarter, underlining that Q1 was not a one‑off sugar high. For investors, these numbers mean the AI story is being underwritten not only by vision statements but by revenue trajectories and margin math.

Argus Joins the Bulls: From “Show Me” to “Buy”

Enter Argus, stage right. The research firm has upgraded Nokia from “hold” to “buy” and set a 12‑month target price of around 15 dollars, placing itself at the top end of current Wall Street expectations. The upgrade argument is remarkably straightforward: accelerating AI‑linked demand, strengthened Network Infrastructure growth targets, and a balance sheet with the flexibility to keep investing while still rewarding shareholders.

Argus is not an outlier shouting into the void. Bank of America (BAC) lifted Nokia to “buy” earlier in April with a target near 12.40 dollars, citing the same optical and AI infrastructure tailwinds that are now showing up in Q1 results. Goldman Sachs moved from “sell” to “neutral,” and the broader analyst community sits in “Strong Buy” territory, with an average target in the low‑double‑digit range. For a stock that has spent years in the penalty box, the re‑rating looks less like a speculative frenzy and more like overdue recognition that the business model has quietly moved up the value stack.

The New Nokia: Wiring the AI Economy

In its previous life, Nokia’s fate was tethered to smartphone cycles and carrier capex moods. Today, its fortunes are increasingly tied to whether the world keeps training large AI models and building the networks needed to move those workloads around. The AI and Cloud segment’s 49% sales growth, Optical Networks’ 20% surge, and the raised 12%–14% Network Infrastructure growth target are the operational backbone of that shift.english.

Analysts like Argus are effectively telling investors that Nokia is no longer just selling telecom plumbing; it is quietly becoming core infrastructure for the AI era—with a cash‑rich balance sheet, improving margins, and a growing queue of hyperscalers and enterprises at the door. In a market crowded with AI narratives, Nokia’s version has one subtle but important advantage: it actually runs over fiber and switches you can touch, measure, and, increasingly, bill at a premium.

The Sources

  1. Nokia Corporation Interim Report for Q1 2026 – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/nokia-corporation-interim-report-q1-050000132.htmlfinance.yahoo
  2. Nokia Corporation Interim Report for Q1 2026 – Nokia (Press Release)
    https://www.nokia.com/newsroom/nokia-corporation-interim-report-for-q1-2026/nokia
  3. Nokia Interim Report Q1 2026 (PDF) – Nokia
    https://www.nokia.com/system/files/2026-04/nokia_results_2026_q1.pdfnokia
  4. Nokia’s Q1 Earnings Match Estimates on Higher Revenues – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/nokias-q1-earnings-match-estimates-150800477.htmlfinance.yahoo
  5. Nokia posts stronger Q1 results as AI, cloud business grows – Xinhua
    https://english.news.cn/20260423/fdc79dfd5688473fa9fb234616ff2d41/c.htmlenglish.news
  6. Nokia Q1 2026 Beats Estimates as AI Network Pivot Pays Off – European Business Magazine
    https://europeanbusinessmagazine.com/business/business-nokia-q1-2026-earnings-ai-network-infrastructure-pivot/europeanbusinessmagazine
  7. AI boom lifts Nokia sales, shares hit 16-year high after earnings beat – Reuters
    https://www.reuters.com/business/nokia-beats-first-quarter-estimates-ai-boom-lifts-sales-again-2026-04-23/reuters
  8. Nokia hails strong start as AI shows promise – Mobile World Live
    https://www.mobileworldlive.com/ranvendors/nokia-hails-strong-start-as-ai-shows-promise/mobileworldlive
  9. Nokia Posts Strong Q1 2026 Growth Driven by AI and Cloud Demand – TechAfrica News
    https://techafricanews.com/2026/04/23/nokia-posts-strong-q1-2026-growth-driven-by-ai-and-cloud-demand/techafricanews
  10. NOK Stock Climbs As AI And 5G Upgrades Draw Wall Street – StocksToTrade
    https://stockstotrade.com/news/nokia-corporation-sponsored-nok-news-2026_04_16/stockstotrade
  11. Nokia Alliances With Orange And RUCKUS Test AI Network Rerating – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/nokia-alliances-orange-ruckus-test-020616780.htmlfinance.yahoo
  12. Nokia expands network portfolio for premium performance in the AI RAN era – Nokia
    https://www.nokia.com/newsroom/nokia-expands-network-portfolio-for-premium-performance-in-the-ai-ran-era-mwc26/nokia
  13. Nokia enjoys optical boom but mobile is still feeling the heat – Light Reading
    https://www.lightreading.com/optical-networking/nokia-enjoys-optical-boom-but-mobile-is-still-feeling-the-heatlightreading
  14. Nokia lifts network growth targets as AI demand powers solid Q1 2026 – TipRanks
    https://www.tipranks.com/news/company-announcements/nokia-lifts-network-growth-targets-as-ai-demand-powers-solid-q1-2026tipranks
  15. The New Nokia: A Bullish Upgrade Ignites This Big AI Bet – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/nokia-bullish-upgrade-ignites-big-145500696.htmlfinance.yahoo
  16. Stock Market Today, April 13: Nokia Surges After Bank of America Upgrade – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/stock-market-today-april-13-212839524.htmlfinance.yahoo
  17. Goldman Sachs Upgrades Nokia (NOK) to Neutral, Raises PT – Yahoo Finance
    https://finance.yahoo.com/markets/stocks/articles/goldman-sachs-upgrades-nokia-nok-110932917.htmlfinance.yahoo
  18. Nokia (NYSE:NOK) Raised to “Buy” at Argus – MarketBeat
    https://www.marketbeat.com/instant-alerts/nokia-nysenok-raised-to-buy-at-argus-2026-04-27/marketbeat
  19. Argus upgrades Nokia stock rating on AI demand, raises target to $15 – Investing.com
    https://www.investing.com/news/analyst-ratings/argus-upgrades-nokia-stock-rating-on-ai-demand-raises-target-to-15-93CH-4637856investing
  20. Analysts Offer Insights on Technology Companies: Nokia (NOK) – The Globe and Mail
    https://www.theglobeandmail.com/investing/markets/stocks/NOK/pressreleases/1524223/analysts-offer-insights-on-technology-compani…theglobeandmail
April 27, 2026

DigitalOcean’s AI Wave: Has Wall Street Finally Found Its Mid‑Cap Cloud Crush? -( $DOCN $NVDA )

DigitalOcean’s (DOCN) latest earnings beat and AI infrastructure push have turned a once-overlooked mid‑cap cloud name into one of Wall Street’s more improbable comeback stories, with the stock up triple digits over the past year and nearly doubling year‑to‑date. The market now has to answer a deceptively simple question: is this still a value play in small‑business cloud, or has the narrative run ahead of the numbers?

Earnings Beat: The Quarter That Rewrote Expectations

DigitalOcean has quietly built a habit that endears companies to analysts: beating estimates with almost boring regularity. Its most recent reported quarter (Q4 2025) delivered non‑GAAP EPS of 0.44 versus expectations of 0.31, a roughly 42% upside surprise layered on nearly 18% year‑over‑year revenue growth. Earlier in 2025, quarters came in similarly strong, with EPS consistently landing 25–45% above consensus and revenue edging past forecasts.

For a company that was once dismissed as “the other cloud,” those beats matter because they accompany a mix shift toward higher‑value AI and larger enterprise‑style customers. Revenue growth is no longer just about selling more low‑end droplets to scrappy developers; it increasingly reflects AI‑native workloads, higher ARPU customers, and expanding margins.

AI Infrastructure: From Budget Cloud To “AI Factory”

If 2022 was the year DigitalOcean learned that multiple compression is real, 2025–2026 is turning into the era where it tries to re‑introduce itself as an AI infrastructure specialist. The company has leaned hard into AI‑native offerings, showcasing production‑ready GPU infrastructure, managed Kubernetes, high‑performance storage, and vector‑ready databases specifically designed for inference‑heavy and agentic workloads.

At NVIDIA’s GTC 2026, DigitalOcean announced an “AI Factory” vision, anchored by a new Richmond data center built exclusively for AI, with NVIDIA HGX B300 systems and 400 Gbps RDMA fabric to keep inference and training pipelines humming. Management isn’t just talking about GPUs; it’s selling a full‑stack environment that threads together compute, storage, networking, and inference into a single, developer‑friendly experience. For AI‑native startups, the pitch is straightforward: hyperscaler‑like capabilities, with fewer line items and less heartburn when the monthly bill arrives.

That value proposition appears to be resonating. AI startups running production models on DigitalOcean report around 50% faster training cycles and roughly 40% lower latency, statistics that sound like marketing copy until you realize they are coming from the company’s own reported customer outcomes. The result is a subtle but important narrative shift from “cheap cloud for small projects” to “purpose‑built AI infrastructure for the mid‑market and emerging enterprise.”

Valuation: Between Fair Value And Fairy Tale

With the stock price having surged, valuation has moved from “contrarian opportunity” to “respectable debate topic at investment committees.” Recent narrative-driven fair‑value models suggest a wide range of outcomes: one widely tracked framework puts fair value around 101.58 per share, just modestly above a recent trading level in the mid‑90s, implying only single‑digit upside from here. Other popular narratives are far less charitable, pegging fair value nearer to 50 per share, well below recent prices and signaling a meaningful risk that expectations have gotten ahead of themselves.

On traditional metrics, DigitalOcean is no longer priced like a distressed asset. Trailing revenue has climbed above 860 million with earnings over 250 million, giving the company a market cap in the mid‑single digit billions and a trailing price‑to‑earnings multiple in the mid‑20s. Previous analysis has flagged the name as expensive relative to its own estimated fair P/E, with a multiple in the high‑30s once you rewind to earlier pricing points in late 2025. Add in forward expectations and the market is effectively underwriting high‑teens revenue growth and sustained margin expansion as the AI infrastructure business scales.

Wall Street has noticed. One major firm, Bank of America, reset its stance on the stock to “buy,” raising its price target to 60 when shares were much lower and explicitly citing the AI pivot, improving demand, and expanding operational leverage as key drivers. More recent consensus data show a “Buy” average rating from roughly a dozen‑plus analysts, even as the average target now sits below the latest trading price—another sign that sentiment ran ahead of published models during the latest rally. In classic fashion, the stock may now be pulling the Street forward rather than the other way around.

Stock Performance: From Left For Dead To Market Darling

If multiple expansion had a highlight reel, DigitalOcean’s recent chart would be in it. Over the last 52 weeks, the stock has advanced roughly 218%, turning a 25‑handle low into a near‑triple‑digit high. Year‑to‑date, the move has been just as dramatic, with shares up about 98% since the end of 2025, as investors re‑rated the business in real time amid better earnings and escalating AI commentary.

Put into context, this is a remarkable reversal. The stock had previously endured brutal drawdowns of more than 70% from its earlier peaks as the market soured on mid‑tier cloud names and punished anything that looked like “growth without a moat.” Now, the same security is posting two‑ and three‑year total returns north of 180–200% from prior trough levels, a whiplash reminder that public markets can be both unforgiving and surprisingly forgiving—just not usually in that order. Momentum investors see a name breaking out on accelerating price and volume, while fundamental investors see a company that has finally managed to align its narrative (AI, operational leverage, higher‑value customers) with its financial statements.

The Investment Question: Durable AI Re‑Rating Or Hot Money Holiday?

For investors, the DigitalOcean setup now pivots on durability: can AI‑driven growth and margin expansion justify a valuation built on near‑perfect execution? The bullish case holds that the company’s niche focus on small and mid‑size businesses, coupled with AI‑native startups fleeing hyperscalers in search of better price‑performance, creates a sticky, under‑served market where DigitalOcean can compound earnings for years. As more workloads shift from experimentation to production, the company’s AI Factory, specialized data centers, and full‑stack cloud offering could deepen switching costs and support premium pricing without losing its reputation as the “developer’s cloud.”

The bear—or at least skeptical—case is more prosaic. At current levels, the stock already bakes in robust growth, sustained AI traction, and continued execution with very little room for macro speed bumps or competitive missteps. Hyperscalers are not in the habit of ceding profitable niches forever; as DigitalOcean proves the economics of AI‑native mid‑market workloads, it may find itself playing a higher‑stakes game of feature catch‑up, price pressure, or both. That leaves little margin for error if revenue growth slows back into the low teens or if AI enthusiasm cools before the business fully transitions into its new role.

For now, the tape is voting loudly in DigitalOcean’s favor, while the models are trying to catch up without abandoning basic math. For serious investors, that makes DOCN less of a simple re‑rating story and more of an ongoing case study: can a niche cloud provider leverage AI to escape the gravity well of commodity infrastructure and earn a premium multiple for the long haul?

The Sources


[1] A Look At DigitalOcean Holdings (DOCN) Valuation After Earnings … https://simplywall.st/stocks/us/software/nyse-docn/digitalocean-holdings/news/a-look-at-digitalocean-holdings-docn-valuation-after-earning
[2] DOCN Performance Report for Digitalocean Holdings Stock – Barchart https://www.barchart.com/stocks/quotes/DOCN/performance
[3] DigitalOcean Holdings (DOCN) Earnings – Public Investing https://public.com/stocks/docn/earnings
[4] DigitalOcean (DOCN) Stock: Breaking Down the 10% Monday Surge https://blockonomi.com/digitalocean-docn-stock-breaking-down-the-10-monday-surge/
[5] DigitalOcean (DOCN): Assessing Valuation After Beating Revenue … https://www.webull.com/news/13555369348891648
[6] DigitalOcean Holdings (DOCN) Stock Price & Overview https://stockanalysis.com/stocks/docn/
[7] DigitalOcean’s Invite to Citi AI Summit Highlights Its Push for… https://marketchameleon.com/articles/b/2026/4/14/digitalocean-citi-ai-summit-ai-inference-cloud
[8] DOCN Stock Chart (Dividends Reinvested, Inflation Adjusted) https://totalrealreturns.com/s/DOCN
[9] DigitalOcean at NVIDIA GTC 2026: Building the AI Factory for the … https://www.digitalocean.com/blog/building-ai-factory-for-agentic-era-nvidia-gtc
[10] AI-Native Startups Are Leaving Hyperscalers for … – DigitalOcean, LLC https://investors.digitalocean.com/news/news-details/2026/AI-Native-Startups-Are-Leaving-Hyperscalers-for-DigitalOceans-Agentic-Inference-Cloud/default.aspx
[11] Assessing DigitalOcean Holdings (DOCN) Valuation After AI … https://finance.yahoo.com/markets/stocks/articles/assessing-digitalocean-holdings-docn-valuation-060652044.html
[12] DigitalOcean’s AI pivot nets new stock price target https://www.thestreet.com/economy/what-digitalocean-did-shocked-wall-street-and-its-only-happened-twice
[13] DigitalOcean Holdings (NYSE:DOCN) Stock Valuation, Peer … https://simplywall.st/stocks/us/software/nyse-docn/digitalocean-holdings/valuation
[14] DOCN DigitalOcean Holdings, Inc. Stock Price & Overview https://seekingalpha.com/symbol/DOCN
[15] DigitalOcean, LLC – Financials – Quarterly Results – Investor Relations https://investors.digitalocean.com/financials/quarterly-results/default.aspx

April 25, 2026

Why the Iran War Hasn’t Raided Your Grocery Cart…Yet -( $ACI $AMZN $COST $KR $TGT $WMT )

Iran’s war and the blockade of the Strait of Hormuz are already roiling oil and fertilizer markets, but the punchline for American shoppers—and investors—is that the real hit to grocery bills, and to the likes of Walmart (WMT), Target (TGT), and Amazon (AMZN), is more likely a 2026–2027 story than a “this week at Costco” moment. The pipeline from higher diesel and fertilizer costs to higher food prices moves with all the urgency of a quarterly earnings call Q&A: slow, deliberate, and just suspenseful enough to keep both consumers and shareholders on edge.

The War, the Strait, and the Silent Surcharge

Iran’s obstruction of the Strait of Hormuz has pinched a major share of global seaborne oil flows and a significant chunk of fertilizer shipments, turning one geographic chokepoint into a multi-quarter risk factor for food and retail margins. Oil prices have jumped, diesel has followed, and the fertilizer market has rediscovered volatility with the enthusiasm of a meme-stock message board.

For big-box bellwethers like Walmart (WMT) and Target (TGT), and e-commerce titan Amazon (AMZN) with its growing grocery footprint through Amazon Fresh and Whole Foods, higher transport and packaging costs are already a line item in risk disclosures—even if not yet a headline in the weekly ad circular. Farmers and food producers are absorbing higher input costs today, while retailers sit in the middle of the value chain, deciding how much to pass through without alienating consumers who have become highly price-sensitive after several years of elevated inflation.

Why Your Grocery Bill Hasn’t Exploded…Yet

The mystery of the relatively tame grocery bill, despite the geopolitical drama, is less a miracle and more a matter of timing, contracts, and inventory cycles. Many large North American farmers locked in fertilizer and diesel purchases for the current growing season before the conflict escalated, muting the immediate blow that might otherwise have rippled more quickly into retail prices at Walmart’s supercenters or Target’s grocery aisles.

Because crops are planted and harvested on an annual rhythm, today’s input shock doesn’t fully translate into shelf prices until future harvests—think more 2026–2027 than “this weekend’s family shop.” Energy-price shocks, by contrast, filter through faster and more broadly, nudging up costs on everything from refrigerated dairy to trucked-in produce. That dynamic matters for Amazon (AMZN), which runs an energy-intensive logistics network, as well as for national grocery chains like Kroger (KR), Costco (COST), and Albertsons (ACI), all of which rely on vast truck fleets and cold-chain infrastructure to keep shelves stocked and freezers humming.

The Lagged March of Food Inflation

History and research on cost pass-through suggest that spikes in energy and agricultural inputs seep into consumer prices gradually and incompletely rather than in one dramatic leap. Firms along the supply chain face menu costs, contractual obligations, and competitive pressures, so they often absorb part of the blow before adjusting price tags—and then typically in stages, not all at once.

For publicly traded grocery and big-box names—Walmart (WMT), Target (TGT), Costco (COST), Kroger (KR), Albertsons (ACI), and Amazon (AMZN)—that means a familiar balancing act between margin protection and market share. Central bankers have seen versions of this movie before: energy and food shocks can add meaningful pressure to headline inflation, but the full impact tends to unfold over several quarters. If the Iran conflict and Strait disruptions persist, food-at-home inflation could re-accelerate, with retailers caught between higher costs at the back door and consumer resistance at the front door.

Farmers on the Front Line, Retailers in the Middle

On the farm side, the math is getting harder even if the supermarket sticker has not yet fully caught up. As diesel, fertilizer, and packaging costs rise, farmers’ margins are squeezed, influencing what gets planted next season and how aggressively producers and processors push for higher prices from their downstream customers—among them the big U.S. chains and platforms that increasingly dominate grocery spending.

Retailers like Walmart (WMT) and Kroger (KR) rely on their scale to negotiate with suppliers and keep “everyday low prices” credible, while Target (TGT) and Costco (COST) lean on curated assortments, private labels, and membership models to protect loyalty even as costs creep higher. Amazon (AMZN), still scaling its food ambitions, faces the dual challenge of managing higher logistics costs and convincing shoppers its digital cart can compete on price with the brick-and-mortar giants. Today’s war premium on inputs, in other words, is setting up tomorrow’s negotiation across the table between suppliers and the largest publicly traded grocery and mass-merchandise players in America.

What This Means for Shoppers and Investors Now

For now, American consumers are living in a strange interlude where the macro headlines scream “inflation risk” while the grocery aisle mostly whispers it. Gas and diesel have moved first, but food-price data show only modest additional pressure so far, thanks to earlier input hedging, inventory buffers, and retailers’ willingness—so far—to eat some of the higher costs to protect traffic and basket size.

For investors in Walmart (WMT), Target (TGT), Amazon (AMZN), Costco (COST), Kroger (KR), Albertsons (ACI), and other food-exposed retailers, the key questions over the next several quarters are classical but newly sharpened by geopolitics: How much cost can these companies absorb before margin compression becomes visible in earnings, and when do they decide to push through a new round of price hikes that consumers will actually feel at the checkout? Until that inflection point, the Iran war remains less a shock at the register and more a slow-moving risk embedded in guidance, commentary on earnings calls, and the fine print of operating margin assumptions—proof that in the global food economy, geopolitics travels on a delay, but it rarely cancels its reservation.

The Sources

Here’s a numbered source list you can drop in at the end of the piece:

  1. Yahoo Finance – “Why the Iran war might not raise your grocery bill until next year”
    https://finance.yahoo.com/economy/policy/article/why-the-iran-war-might-not-raise-your-grocery-bill-until-next-year-120223060.html[1]
  2. Fortune – “The Iran war is exacerbating already high grocery bills”
    https://fortune.com/2026/04/08/iran-war-high-grocery-prices-getting-worse[2]
  3. Business Insider – “The Iran War Could Haunt Grocery Bills Long After the Fighting Stops”
    https://www.businessinsider.com/iran-war-fertilizer-shortage-grocery-inflation-long-after-fighting-stops-2026-4[3]
  4. CNBC – “Grocery shock on the horizon for U.S. elections as Iran war drags on”
    https://www.cnbc.com/2026/04/02/grocery-shock-on-the-horizon-for-us-elections-as-iran-war-drags-on.html[4]
  5. MarketWatch – “Your grocery bill will be the next casualty of the Iran war”
    https://www.marketwatch.com/story/you-think-iran-is-only-about-oil-no-its-also-about-your-dinner-table-636de6a5[5]
  6. IFPRI – “The Iran war’s impacts on global fertilizer markets and food production”
    https://www.ifpri.org/blog/the-iran-wars-impacts-on-global-fertilizer-markets-and-food-production[6]
  7. Goldman Sachs – “How the Conflict in the Strait of Hormuz Could Affect Global Agriculture Prices”
    https://www.goldmansachs.com/insights/articles/how-the-conflict-in-the-strait-of-hormuz-could-affect-global-agriculture-prices[7]
  8. The Jerusalem Post – “Hormuz closure disrupts global fertilizer trade, raising food prices”
    https://www.jpost.com/international/article-892976[8]
  9. ABC News Daily (podcast) – “When will the Iran war hit your grocery bill?”
    https://www.youtube.com/watch?v=Yhn-dNyx6Ao[9]
  10. Democracy Now – “The Looming Food Crisis: Why the Strait of Hormuz Is Disrupting Global Food and Fertilizer Supplies”
    https://www.democracynow.org/2026/4/23/adam_hanieh[10]

April 25, 2026

Why X-Energy’s Nuclear IPO Has AI Data Centers Glowing -( $AMZN $CPYFF $DOW $NVDA $XE )

X-Energy’s stock-market debut delivered exactly what Wall Street loves: a big narrative, bigger numbers, and just enough nuclear jargon to make everyone feel smarter reading about it. The Amazon.com Inc. (AMZN)–backed reactor developer X-Energy Inc. (XE) raised about $1.02 billion in its initial public offering, then promptly watched its shares jump roughly 27% above the IPO price as investors decided that small modular reactors might be the new large-cap story.

A Nuclear IPO That Refused To Stay Small

X-Energy came to market marketing its IPO at between 16 and 19 dollars a share, then priced at 23 dollars after demand proved more energetic than even its own advanced fuel. The company sold roughly 44.3 million shares, giving it an initial market value of about 9.1 billion dollars based on its regulatory filings, before trading enthusiasm pushed its valuation higher in early sessions.

On its first day, shares opened more than 30% above the IPO price and settled still up about 27%, a performance that placed X-Energy among the more notable recent U.S. listings and underscored growing investor appetite for nuclear-themed energy solutions. For a sector that not long ago was better known for regulatory headaches than headline-grabbing debuts, the showing suggested that “nuclear” may now scan less as a four-letter word and more as an AI-adjacent growth category.

Amazon’s New Kind of Prime Power

Amazon’s interest in X-Energy extends beyond simple financial curiosity; the e‑commerce and cloud computing giant has been exploring nuclear as a way to feed the power-hungry growth of Amazon Web Services data centers. With artificial intelligence workloads driving energy demand higher, X-Energy’s next-generation reactors are being positioned as bespoke power plants for industrial campuses and AI data farms rather than as traditional grid-scale behemoths.

The partnership places AMZN in an unusual role: potential anchor customer, strategic backer, and case study in how hyperscalers might secure long-duration, carbon-free baseload power. In an era when cloud providers worry that electricity could become the new bottleneck for growth, having a nuclear specialist on speed dial may be the new version of owning your own undersea cables.

Dow and Centrica Bring Industrial Credibility

If Amazon supplies the tech buzz, Dow Inc. (DOW) and Centrica Plc (CPYYF) offer the industrial bona fides. X-Energy is developing more than 11 gigawatts of new nuclear capacity through commercial partnerships in the U.S. and UK, including a proposed four‑unit Xe‑100 plant for Dow in Texas to power energy‑intensive chemical operations.

Centrica, the British multinational energy and services group, has committed to up to 6 gigawatts of capacity tied to X-Energy’s technology, signaling European interest in modular nuclear solutions amid efforts to decarbonize heavy industry and secure reliable supply. Between DOW’s industrial heat demand and CPYYF’s energy portfolio, the company’s pipeline looks more like a long-term infrastructure schedule than a speculative science project.

The Reactor: Pebbles, Helium and a Safety Pitch

At the core of X-Energy’s story is the Xe‑100, an 80‑megawatt high‑temperature gas‑cooled reactor that uses helium as coolant and fuel pebbles filled with so‑called TRISO pellets. Each pebble contains tiny uranium kernels embedded in protective layers, a design meant to keep the fuel structurally intact even at very high temperatures and to naturally slow the reaction as heat rises.

Because the Xe‑100 is modular, units can be manufactured in a more standardized way and then deployed as needed, a concept intended to avoid the notorious cost overruns of bespoke, single‑site mega‑reactor projects. X‑Energy also produces its own TRISO‑X fuel, giving it tighter control over supply chains than competitors that rely on third‑party fuel vendors, a detail that investors have treated as a small but meaningful moat.

Government Support and a Second Chance at Going Public

X-Energy’s path to Nasdaq was not a straight line. The company previously planned to go public via a special-purpose acquisition company linked with Ares Acquisition but scrapped that deal in 2023 amid a chill in SPAC markets and concerns triggered by the cancellation of another U.S. small modular reactor project.

In the interim, the company kept attracting capital, raising hundreds of millions of dollars from private investors, including a 700 million dollar Series D round led by Jane Street Group. Its development efforts have also benefited from U.S. Department of Energy support through programs such as the Advanced Reactor Demonstration Program, which aims to help bring new reactor designs to commercial deployment. For policy-watchers, it’s a reminder that sometimes Washington’s long timelines and Wall Street’s short attention spans do eventually intersect in the same prospectus.

The AI Energy Arms Race

The timing of X-Energy’s IPO has coincided with a broader market narrative: artificial intelligence as both the driver of and solution to an energy crunch. As data centers deploy more accelerators from semiconductor leaders such as NVIDIA Corp. (NVDA) to run large AI models, their electricity demand grows faster than local grids can comfortably accommodate, strengthening the case for colocated, high‑reliability power.

X-Energy is positioning its Xe‑100 reactors as tailored answers to that power challenge, capable of serving not just data centers but also industrial customers that need high‑temperature steam and steady baseload power with low direct emissions. The market response to XE’s debut indicates that investors are increasingly comfortable treating nuclear power as a potential beneficiary of the AI build‑out, rather than as a regulatory footnote in the climate discussion.

Ark, Amazon and the New Nuclear Basket

Among the institutional names circling the offering is Ark Investment Management, the high‑profile fund complex known for concentrating bets on disruptive technologies. Ark signaled interest in purchasing up to 105 million dollars’ worth of shares at the IPO price, a detail that helped frame XE as a member of the same thematic universe as high‑growth innovators across energy, automation, and AI.

For Amazon shareholders, the move adds another line to the company’s already eclectic roster of strategic initiatives, which ranges from e‑commerce and streaming to satellite networks and healthcare. While the financial impact of any single energy partnership is likely to be modest for a company the size of AMZN, the symbolic impact—tying its AI ambitions to a clearer long‑term energy strategy—may be harder for investors to ignore.

A Market That Suddenly Likes Atoms Again

X-Energy’s post‑IPO valuation climbed into the low double‑digit billions, marking a swift upsizing from its earlier SPAC-era aspirations and underscoring how quickly sentiment around nuclear can change when the story is framed as climate‑friendly and AI‑ready. Less than three years after pulling its prior listing plans, the company now stands as one of the more prominent publicly traded pure‑play developers of advanced nuclear reactors.

Investors still face the usual questions: regulatory timelines, construction risk, and the challenge of bringing first‑of‑a‑kind reactors into commercial service by the early 2030s. But for now, the market message is straightforward: in a world racing to power its algorithms and decarbonize heavy industry at the same time, ticker XE has entered the conversation—and this time, the atoms are getting the kind of multiple usually reserved for bits.

The Sources


[1] Amazon-Backed Nuclear Firm X-Energy Raises $1.02 Billion in IPO https://finance.yahoo.com/markets/stocks/articles/amazon-backed-nuclear-firm-x-001155364.html
[2] Amazon-Backed X-Energy Climbs 27% After $1.02 Billion US IPO https://www.bloomberg.com/news/articles/2026-04-24/amazon-backed-x-energy-climbs-31-after-1-02-billion-us-ipo
[3] X-Energy IPO Set to Deliver Big Wins to Amazon and Ken Griffin – WSJ https://www.wsj.com/finance/investing/x-energy-ipo-xe-stock-6b96c412
[4] Amazon-backed X-Energy raises over $1 billion in IPO | Reuters https://www.reuters.com/business/energy/amazon-backed-x-energy-raises-102-billion-ipo-2026-04-24/
[5] Amazon-backed nuclear developer X-energy surges 27% in trading … https://www.ft.com/content/905d06cf-9b28-494a-be26-4a64f8269b73?syn-25a6b1a6=1
[6] Amazon-Backed Nuclear Tech Company X-Energy Raises Over $1 … https://www.esgtoday.com/amazon-backed-nuclear-tech-company-x-energy-raises-over-1-billion-in-ipo/
[7] X-energy raises $1B in the largest nuclear public equity offering of … https://techfundingnews.com/x-energy-1b-nasdaq-ipo-advanced-nuclear-reactors/
[8] X-energy – Wikipedia https://en.wikipedia.org/wiki/X-energy
[9] Amazon-backed nuclear startup X-Energy raises $1.02B in IPO (XE:Pending) https://seekingalpha.com/news/4579196-amazon-backed-nuclear-startup-x-energy-raises-102b-in-ipo
[10] Nuclear Start-Up X-Energy Is About to Go Public. Amazon Is an Investor. https://www.barrons.com/articles/-x-energy-nuclear-ipo-amazon-72db4288
[11] Amazon-Backed Nuclear IPO X-Energy Quickly Jumps 27 … – Barron’s https://www.barrons.com/articles/x-energy-ipo-stock-ticker-today-f7553a76
[12] X-energy – LinkedIn https://www.linkedin.com/company/x-energy
[13] How to Write Headlines Like The Wall Street Journal https://raganconsulting.com/5-tips-to-write-headlines-from-the-wall-street-journal/
[14] Amazon-Backed Nuclear Firm X-Energy Raises $1.02 Billion in IPO https://www.youtube.com/watch?v=EGoP1OQnZ5s
[15] Your Three-Minute Guide to WSJ.com https://www.wsj.com/edition/resources/documents/quickref-find.html

April 24, 2026

April 24, 2026 – AI Chips, Hot PMIs, and Cooler Heads: A Week Where Macro Tried to Matter -( $AMZN $APLD $AVGO $EPRX $INTG $NOK $NVDA $OPEN $SOAR $WMT Rise!)

US equities wrapped the week on a mixed but tech-led footing, with AI and semis doing the heavy lifting while macro data and Middle East risk kept a lid on cyclicals and financials.

Index performance and risk tone

By end of the day Friday, the S&P 500 was up roughly 0.8%, around 7,165, confirming a fourth straight week of gains, while the Nasdaq was up 1.63% as chipmakers extended their outperformance. The Dow lagged, trading slightly lower as weakness in cyclicals and financials offset the tech bid.

Across the week, investors looked past lingering Middle East tensions and an uneasy standoff around Hormuz, leaning back into growth and AI plays even as broader global indices showed more muted or negative returns. Volatility stayed elevated but contained, reflecting a market that is repricing sector winners and losers rather than wholesale de‑risking.

Macro data and policy narrative

The macro backdrop was defined less by a single blockbuster data print and more by a steady stream of indicators that support the “resilient but slowing” growth narrative heading into the coming Fed meeting. PMI readings highlighted a divergence: euro area composite PMI slipped back into contraction territory in April, while US manufacturing reached a four‑year high as firms pulled forward orders amid concerns about supply disruptions.

On the policy front, markets spent the week positioning ahead of late‑April and early‑May central bank decisions, with particular focus on how sticky services inflation and firm labor demand might constrain the Fed’s ability to ease. The IMF’s April World Economic Outlook reinforced this cautious stance, projecting global growth near 3.1% for 2026 with a modest uptick in headline inflation before pressures ease again in 2027, underscoring that policymakers must juggle both downside growth risks and renewed price pressures.

AI, semis, and Nvidia’s $5T club

AI enthusiasm again dominated equity leadership, with semiconductor indices extending a powerful multi‑month run; one widely tracked chip index is now up more than 50% over the past six months and has logged gains in each of the last 17 sessions. Within that backdrop, Nvidia (NVDA, $208.27, +4.32%) reclaimed the headlines as its market capitalization pushed back above the $5 trillion threshold, reasserting its status as the market’s core AI bellwether.

This $5T zone is not new for Nvidia—last year it became the first public company to close above that level—but the latest move comes after the company reported record fiscal‑year revenue of about $216 billion and a blowout Q4 driven by an AI data‑center run rate north of $190 billion annually. Looking ahead, investors are now laser‑focused on Nvidia’s upcoming May 20 earnings, where management has guided to roughly $78 billion in Q1 revenue, even as competition from Broadcom (AVGO, $422.76, +3.99% over the last 5-days) and hyperscalers like Amazon(AMZN, $263.99, +5.365 over the last 5-days) intensifies in custom AI silicon.

Earnings season: Intel and sector rotation

Earnings flow this week reinforced the bifurcation within tech. Intel (INTC, $82.54) became a major story on Friday as the stock surged more than 20% after posting stronger‑than‑expected profit and issuing upbeat guidance tied to AI‑driven data‑center and foundry demand, sparking a broad rally across legacy chip and PC‑exposed names. That strength helped offset softness in cyclicals and financials, which struggled under the weight of higher‑for‑longer rate fears and a flatter curve narrative.

Outside the US, equity markets were more cautious: European indices were mixed despite weak PMI data, and several Asia‑Pacific bourses ended lower as investors de‑risked around geopolitical headlines and energy price volatility. The divergence between US mega‑cap tech and the rest of the global equity complex remains stark, adding to debate about concentration risk and the sustainability of the AI‑led melt‑up.

Big‑picture takeaway for the week

For the week ending Friday, April 24, 2026, the dominant theme was “AI strength versus macro skepticism”: Nvidia’s return to the $5 trillion club and Intel’s breakout kept the Nasdaq and S&P on an upward trajectory, even as global growth forecasts softened and geopolitical risk stayed front and center. With a heavy macro calendar and a pivotal Fed meeting on deck, the market now faces a familiar test: can earnings and AI capex momentum continue to outrun concerns about policy constraints, inflation flare‑ups, and concentrated leadership at the top of the tape.

VP Watchlist Updates

Below is an update‑style snapshot on the VP Watchlist names for the week, focused on recent catalysts, positioning, and narrative rather than precise price moves.

Applied Digital (NASDAQ: APLD, $34.98, +10.94% over the last 5-days)

In late April, Applied Digital (APLD) inked a roughly 15-year, $7.5 billion lease with a new U.S.-based, high investment-grade hyperscaler at its 430 MW Delta Forge 1 “AI Factory” campus, securing 300 megawatts of critical IT load dedicated to AI and high-performance computing. The deal lifts the company’s total contracted lease revenue to more than $23 billion and brings its hyperscale tenant roster to three, with over half of that backlog supported by investment-grade customers.

Broadcom (AVGO, $422.76, +3.99% over the last 5-days)

Broadcom’s latest AI alliance with Google parent Alphabet Inc. (GOOGL, GOOG) and Anthropic is less a routine chip deal and more a declaration that the quiet power behind the cloud plans to stay loud for the next decade. The three-way pact locks in custom AI silicon and multi‑gigawatt compute capacity that could reshape who really controls the tollbooths on the generative AI superhighway.

Eupraxia Pharmaceuticals (EPRX, $7.16, +.85% over the last 5-days)

Eupraxia Pharmaceuticals Inc. (EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced 36-week tissue health and symptom data from patients in the highest dose cohort from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). Dr. James A. Helliwell, Chief Executive Officer of Eupraxia stated, “We are very pleased with the robust and sustained response in both tissue health and symptom data in the highest dose cohort at 36 weeks. This data is consistent with the compelling results we observed at earlier timepoints at this dose level, highlighting the potential to achieve both strong and durable responses after a single administration of EP-104GI. We are also reassured by the excellent safety outcomes across all doses in the trial as we continue to observe no indication of drug related SAEs or spikes in glucose or cortisol. We look forward to the results of the placebo-controlled Phase 2b portion of the study where the same dose is being further evaluated”.

Eupraxia recently co-hosted a Tribe Public www.TribePublic.com, CEO Presentation & Q&A Webinar event, Wednesday, April 1 titled “Turning EOE Into a Once-a-Year Appointment.” The event featured James A. Helliwell, M.D., Co‑founder and CEO of Eupraxia Pharmaceuticals (NASDAQ: EPRX), who discusses the company’s precision drug‑delivery platform, its approach to Eosinophilic Esophagitis (EoE), and broader pipeline priorities, followed by a focused 5–10 minute Q&A. You may watch it now at this Youtube link.

Eupraxia announced (March 17) positive symptom data from patients in the two highest dose cohorts from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis (“EoE”). “We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose of the Phase 1b/2a portion of the RESOLVE study,” said Dr. James A. Helliwell, Chief Executive Officer of Eupraxia. “We believe this type of response based on a single administration procedure would represent a compellingly different option for EoE patients. Importantly, the response that we are observing across cohorts 4-9 has increased as patients progress through the study through to week 24. We believe this demonstrates the importance of stable, continuous long-term local steroids in tamping down signs of inflammation quickly and acting on fibrosis in the longer term. Also, as previously reported, we continue to be encouraged by the safety profile that we have observed with EP-104GI. Currently, with 31 patients dosed in the Phase 1b/2a study, and over 220 months of follow up, there have been no reported serious adverse events.”

Modular Medical (MODD, $4.86)

  • Modular Medical, Inc. (NASDAQ:MODD), a leader in innovative, patient-centric insulin delivery, today announced the pricing of a registered direct offering consisting of 750,000 shares of the Company’s common stock at an offering price of $4.50 per share. The gross proceeds to the Company from the Offering are estimated to be approximately $3.4 million before deducting placement agent fees and other offering expenses. The Offering is expected to close on or about April 21, 2026, subject to the satisfaction of customary closing conditions.
  • Modular Medical’s latest regulatory milestone upgrades the narrative: the company has now secured FDA 510(k) clearance for its Pivot tubeless insulin patch pump, moving from “launch‑ready” to “launch‑approved” in the heart of the fast‑growing diabesity market. The FDA has cleared Modular Medical’s Pivot patch pump as a tubeless, removable insulin delivery system, formally validating the device’s design and performance for commercial use in U.S. adults living with diabetes. The clearance converts what had been a Q1 2026 launch “subject to FDA response” into a tangible commercial pathway, giving the company permission to sell into an insulin pump market that has been estimated at roughly 8 billion dollars globally. Pivot is engineered as a simplified, two‑part patch pump with a 3‑milliliter removable reservoir, no need for battery recharging, and the ability to bolus without a dedicated controller, aiming squarely at patients who have stayed on multiple daily injections because traditional pumps felt too complex, cumbersome, or costly. By clearing Pivot, the FDA is effectively endorsing Modular Medical’s attempt to make advanced insulin delivery feel less like adopting a gadget and more like upgrading a daily habit.

The InterGroup Corporation (INTG, $36.58, +9.85% over the last 5-days)

  • InterGroup Corporation delivered (Feb. 17) a notably stronger quarter, highlighted by a 20% jump in total revenue to $17.3 million and a 27% surge in hotel revenue as renovated rooms returned to service and travel demand improved. The company swung from a prior-year net loss to $1.0 million in net income, with operating income more than doubling to $2.0 million, underscoring better cost control and improved operating efficiency. Management further enhanced liquidity and sharpened strategic focus by selling a non-core 12‑unit Los Angeles multifamily property, generating a meaningful gain and additional working capital while maintaining stable performance across its real estate portfolio.

Volato Group, Inc. (SOAR, +1.33% over the last 5-days) & M2i Global, Inc. (MTWO)

NVIDIA (NVDA, $208.27, +3.27% over the last 5-days) & Nokia (NOK, $10.46, +1.45% over the last 5-days)

  • Nokia just served Wall Street a quietly confident Q1, the kind of quarter that doesn’t light up the meme feeds but does make long-only portfolio managers reach for their notebooks instead of the antacids.
  • In an AI market obsessed with GPUs and stardust, Nokia (NOK) is quietly reminding investors that none of this magic moves without serious plumbing. While Nvidia (NVDA) prepares to headline its GTC 2026 “Woodstock of AI” showcase, the chip giant has already written a very real check to Nokia, committing a $1 billion investment to help rewire the world’s networks for 5G‑Advanced, 6G, and AI‑native workloads. The message is simple enough: GPUs may be the new rock stars, but networking is the stadium.
  • Nvidia delivered strong fourth-quarter results recently, posting revenue of $68.1 billion, well above analyst expectations. Looking ahead, the company projects $7.8 billion in revenue for the first quarter of 2026, reflecting continued robust demand for its AI chips even amid broader market headwinds.
  • NVIDIA and Nebius Group N.V. (NASDAQ: NBIS) (March 11) announced a strategic partnership to develop and deploy the next generation of hyperscale cloud for the AI market, from AI natives to enterprises. NVIDIA will invest $2 billion in Nebius.

McDonald’s (MCD, $299.36)

  • Morgan Stanley (April 21) has adjusted its price target on McDonald’s (MCD) to $334, maintaining an Equal Weight stance on the stock . The firm’s analyst highlighted consumer strength heading into first-quarter results, noting that earnings quality will likely vary across the restaurant and food distribution landscape . While some operators may face headwinds, the underlying consumer backdrop remains robust, which could support McDonald’s performance as one of the industry’s quality players positioned to navigate the current environment .

Opendoor (OPEN, $5.56., +4.61% over the last 5-days)

  • April 16, Opendoor Technologies Inc. (OPEN) announced that it will report first quarter 2026 financial results for the period ended March 31, 2026 following the close of the market on Thursday, May 7, 2026. On May 7, 2026, management will host our Financial Open House video livestream at 2:00 p.m. PT (5:00 p.m. ET) to discuss the company’s business and financial results. We invite shareholders to participate directly through Robinhood’s Say Technologies platform by visiting https://app.saytechnologies.com/opendoor-2026-q1
  • Opendoor Technologies, a leading e-commerce platform for residential real estate transactions, reported financial results for its fourth quarter and year ended December 31, 2025. They highlighted the following: October 2025 acquisition cohort tracking as best-performing October in Company history; acquisitions increased 46% quarter-over-quarter while inventory days in possession reduced 23%.
  • Opendoor continues to navigate a challenging housing backdrop characterized by still‑elevated mortgage rates and tight existing‑home inventories, which weigh on transaction volumes even as affordability slowly improves. The company’s focus on disciplined acquisition spreads, inventory turns, and ancillary services remains central to the investment debate as markets handicap the pace and magnitude of any 2026 housing recovery.

Tesla (TSLA, $376.30)

Reportedly, Tesla unexpectedly swung to positive free cash flow in the first quarter, a neat trick for a company many on Wall Street still expected to be busily torching cash. The electric-vehicle maker has yet to fully open the spending spigots on artificial intelligence and added manufacturing capacity, suggesting the real splurge is still to come.

Serina Therapeutics (NYSE: SER, $1.97)

Serina Therapeutics (NYSE: SER) (www.serinatx.com) seems to have have just traded itself into Wall Street’s good graces, pairing fresh capital with a late-session pop that suggests investors are finally starting to connect the dots between polymer chemistry and portfolio returns. In Huntsville, Alabama, Serina Therapeutics announced definitive agreements for a private placement of common stock and pre-funded warrants that could bring in up to 30 million dollars in gross proceeds. The first 15 million dollar tranche is expected to close on March 20, 2026, with a second tranche of up to 15 million dollars anticipated by April 30, 2026, subject to customary closing conditions.

What makes the deal stand out in a biotech tape crowded with discounts is the pricing: the securities are being sold at about 2.25 dollars per share, a roughly 68 percent premium to Serina’s March 17 closing price, signaling that insiders are willing to pay up for exposure to the company’s clinical agenda. The financing also adds board-level heft, with director Greg Bailey, M.D., stepping into a Co-Chairman role as he leads the investment, a move that effectively puts the capital and the governance on the same optimistic page. Learn more here.

Walmart (WMT, $129.92, +1.90% over the last 5-days)

Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. 

The Sources

  1. Nvidia hits $5 trillion valuation as AI boom powers meteoric rise – Reuters
    https://www.reuters.com/business/nvidia-poised-record-5-trillion-market-valuation-2025-10-29/reuters
  2. Nvidia becomes first company to close above $5 trillion market cap – Yahoo Finance
    https://finance.yahoo.com/news/nvidia-becomes-first-company-to-close-above-5-trillion-market-cap-133101442.htmlfinance.yahoo
  3. As Nvidia crosses $5 trillion, 5 charts on the unstoppable tech rally – Morningstar
    https://www.morningstar.com/markets/nvidia-crosses-5-trillion-5-charts-unstoppable-tech-rallymorningstar
  4. Nvidia is first company worth $5 trillion – NBC News
    https://www.nbcnews.com/business/markets/nvidia-record-five-trillion-ai-bubble-rcna240447nbcnews
  5. NVIDIA (NVDA) – Market capitalization – CompaniesMarketCap
    https://companiesmarketcap.com/nvidia/marketcap/companiesmarketcap
  6. S&P 500, Nasdaq close at records after U.S. extends Iran ceasefire – CNBC
    https://www.cnbc.com/2026/04/21/stock-market-today-live-updates.htmlcnbc
  7. S&P 500 rises as Intel soars, investors bet on Iran talks restarting – CNBC
    https://www.cnbc.com/2026/04/23/stock-market-today-live-updates.htmlcnbc
  8. United States Stock Market Index (US500) – Trading Economics
    https://tradingeconomics.com/united-states/stock-markettradingeconomics
  9. World Economic Outlook, April 2026 – International Monetary Fund
    https://www.imf.org/en/publications/weo/issues/2026/04/14/world-economic-outlook-april-2026imf
  10. Global Economic Outlook: Analyzing the IMF’s April 2026 Report – Investing.com
    https://www.investing.com/analysis/global-economic-outlook-analyzing-the-imfs-april-2026-report-200678466investing
  11. Macroeconomic Forecast – April 2026 – Ministry of Finance, Czech Republic
    https://mf.gov.cz/en/fiscal-policy/macroeconomic-analysis/macroeconomic-forecast/2026/macroeconomic-forecast-april-2026-63635mf
  12. Stock Market Live April 22, 2026: S&P 500 (SPY) Rises on Cease Fire News Again – 24/7 Wall St.
    https://247wallst.com/investing/2026/04/22/stock-market-live-april-22-2026-sp-500-spy-rises-on-cease-fire-news-again/247wallst

Your Guide To Staying Informed In The Markets

Subscribe For Free Email Updates Access To Exclusive Research

Vista Partners — © 2026 — Vista Partners LLC (“Vista”) is a Registered Investment Advisor in the State of California. Vista is not licensed as a broker, broker-dealer, market maker, investment banker, or underwriter in any jurisdiction. By viewing this website and all of its pages, you agree to our terms. Read the full disclaimer here

Copyright © 2026 Vista Partners, LLC. All rights reserved